Amicus Therapeutics, Inc. (FOLD) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $14.49 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 22, 2026 | Dennis Ding | Jefferies | $14.50 | +0.1% |
| Oct 17, 2024 | Tazeen Ahmad | Bank of America Securities | $15.00 | +3.5% |
| May 14, 2024 | Debjit Chattopadhyay | Guggenheim | $13.00 | -10.3% |
| May 9, 2024 | Jeffrey Hung | Morgan Stanley | $19.00 | +31.1% |
| Dec 19, 2023 | Jeffrey Hung | Morgan Stanley | $20.00 | +38.0% |
| May 10, 2021 | Salveen Richter | Goldman Sachs | $14.00 | -3.4% |
Top Analysts Covering FOLD
FOLD vs Sector & Market
| Metric | FOLD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.86 | 2.24 | 2.41 |
| Analyst Count | 7 | 8 | 18 |
| Target Upside | +0.1% | +1150.3% | +14.9% |
| P/E Ratio | -165.17 | 7.02 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $183M | $184M | $184M | 4 |
| 2026-09-30 | $196M | $198M | $200M | 2 |
| 2026-12-31 | $209M | $211M | $214M | 3 |
| 2027-03-31 | $183M | $185M | $187M | 3 |
| 2027-06-30 | $198M | $200M | $203M | 2 |
| 2027-09-30 | $215M | $217M | $219M | 2 |
| 2027-12-31 | $269M | $271M | $275M | 3 |
| 2028-12-31 | $1.09B | $1.10B | $1.10B | 5 |
| 2029-12-31 | $1.28B | $1.31B | $1.34B | 2 |
| 2030-12-31 | $1.44B | $1.47B | $1.50B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.08 | $0.09 | $0.09 | 1 |
| 2026-09-30 | $0.11 | $0.11 | $0.11 | 1 |
| 2026-12-31 | $0.12 | $0.12 | $0.12 | 1 |
| 2027-03-31 | $0.10 | $0.10 | $0.10 | 1 |
| 2027-06-30 | $0.13 | $0.13 | $0.13 | 1 |
| 2027-09-30 | $0.18 | $0.18 | $0.18 | 1 |
| 2027-12-31 | $0.42 | $0.43 | $0.44 | 1 |
| 2028-12-31 | $0.75 | $0.91 | $1.05 | 4 |
| 2029-12-31 | $1.32 | $1.36 | $1.40 | 2 |
| 2030-12-31 | $1.62 | $1.67 | $1.72 | 2 |
Frequently Asked Questions
What is the analyst consensus for FOLD?
The consensus among 7 analysts covering Amicus Therapeutics, Inc. (FOLD) is Hold with an average price target of $14.50.
What is the highest price target for FOLD?
The highest price target for FOLD is $20.00, set by Jeffrey Hung at Morgan Stanley on 2023-12-19.
What is the lowest price target for FOLD?
The lowest price target for FOLD is $13.00, set by Debjit Chattopadhyay at Guggenheim on 2024-05-14.
How many analysts cover FOLD?
7 analysts have issued ratings for Amicus Therapeutics, Inc. in the past 12 months.
Is FOLD a buy or sell right now?
Based on 7 analyst ratings, FOLD has a consensus rating of Hold (2.86/5) with a +0.1% upside to the consensus target of $14.50.
What are the earnings estimates for FOLD?
Analysts estimate FOLD will report EPS of $0.09 for the period ending 2026-06-30, with revenue estimated at $184M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.